Eli Lilly Fails to Overturn $20 Million Cialis Patent Decision

By Greg Langlois, Bloomberg BNA

A jury decision that Eli Lilly and Co. infringed a patent by selling its famed Cialis drug for treatment of enlarged prostate will stand.

In April, a jury awarded Germany-based Erfindergemeinschaft UroPep GbR $20 million in damages after finding Eli Lilly infringed UroPep’s U.S. Patent No. 8,791,124. UroPep filed suit in federal court last year, alleging that Eli Lilly infringed its patent by marketing and selling its erectile dysfunction drug Cialis as a treatment for benign prostatic hyperplasia. BPH is a noncancerous enlarged prostate, which can irritate or block the bladder.

The market for BPH ...